Name: Bipolar Spectrum Diagnostic Guide for Primary Care
Creator: Dr. Arnold Shapiro, MD

Why This Tool Exists

Bipolar disorder is one of the most commonly misdiagnosed conditions in medicine. 69% of bipolar patients are initially misdiagnosed, most commonly as unipolar depression. The average time to correct diagnosis is 5–8 years. Primary care physicians see these patients first — and the right tools can change outcomes dramatically.

This interactive guide transforms a static 17-page PDF into a dynamic clinical decision support tool. Every screening instrument is clickable, auto-scored, and interpreted. Every checklist tallies in real time. Every section includes "Why am I asking this?" education at the point of care.

Clinical Scenario

A patient with heavy alcohol and drug use presents with depression and suicidal ideation. She has been treated with fluoxetine 80 mg without benefit. She is unsure whether she has ever experienced a manic or hypomanic episode. The question: Does she have bipolar spectrum disorder, and if so, how should her treatment differ?

Why This Matters

Up to 40–70% of bipolar patients have comorbid substance use disorders
~40% of bipolar patients are initially misdiagnosed as unipolar depression
Antidepressant monotherapy can worsen bipolar illness: destabilize mood, increase cycling, raise suicidality
High-dose SSRI nonresponse is itself a red flag for underlying bipolarity
Correct diagnosis changes treatment entirely: mood stabilizers replace or accompany antidepressants

69%

Initially misdiagnosed

5–8 yr

Avg time to correct dx

40%

Treatment-resistant depression is actually bipolar

48%

Seen 3+ doctors first

What This App Includes (Beyond the Original PDF)

Module	What It Does	New vs PDF
Rapid Mood Screener (RMS)	6-item quick gate screen with auto-scoring	NEW
Digital Bipolarity Index	First-ever interactive version of Sachs' 5-domain clinician tool	NEW
Mixed Features Screener	DSM-5 mixed features specifier detection	NEW
Red Flag Pattern Engine	Analyzes treatment history and flags bipolar probability	NEW
25-Item Signs Checklist	Interactive, weighted by indicator strength, auto-interprets	Enhanced
DIG FAST Interview	Interactive with patient-friendly questions	Enhanced
Patient Self-Assessment	16-item patient handout with auto-scoring	Enhanced
Bipolar vs Unipolar Table	Side-by-side feature comparison	Enhanced
Treatment Decision Framework	Step-by-step with medication guide	Enhanced
Auto-Generated Clinical Summary	Printable report combining all completed assessments	NEW
Decision Flowchart	Interactive step-by-step diagnostic pathway	Enhanced
Key Statistics Dashboard	Comorbidity rates, misdiagnosis data, prevalence	Enhanced

The Bipolar Spectrum Concept

Bipolar disorder exists on a continuum from mild cyclothymic temperament through bipolar spectrum disorder (subthreshold) to full bipolar II and bipolar I. At least 25% of patients diagnosed with recurrent unipolar depression may be better classified as bipolar spectrum.

Normal

Cyclothymic

Spectrum

Bipolar II

Bipolar I

Increasing severity → (Based on Ghaemi et al., ISBD Diagnostic Guidelines, 2008)

Estimated Prevalence in Recurrently Depressed Patients

Bipolar I: ~1%

Bipolar II: ~3%

Bipolar Spectrum: ~5%

Other/Unipolar: 91%

In SUD populations, rates are even higher — up to 24–48% depending on criteria used.

Diagnostic Overlap Challenge

Substance use can mimic, mask, or coexist with both bipolar and unipolar depression. Symptom overlap makes differentiation difficult, especially when the patient is actively using. Periods of sobriety are the most reliable windows for assessment.

Signs of Bipolarity: Interactive Master Checklist

The International Society for Bipolar Disorders (ISBD) identifies these features as more common in bipolar than unipolar illness. Check each feature present in your patient. The score and interpretation update automatically.

0 / 25

Signs of Bipolarity Present

Low probability of bipolarity — Standard unipolar depression treatment; monitor

Interpretation Guide

Signs Present	Clinical Interpretation	Recommended Action
0–1	Low probability of bipolarity	Standard unipolar depression treatment; monitor
2–3	Possible bipolar spectrum — warrants further evaluation	Administer screening tools (MDQ, BSDS, HCL-32); obtain collateral history
4–6	Probable bipolar spectrum disorder	Strongly consider mood stabilizer; avoid antidepressant monotherapy; psychiatric referral
7+	High probability of bipolar disorder	Treat as bipolar; initiate mood stabilizer; psychiatric consultation; safety planning

Special Consideration: Patients with SUD

In patients with active SUD, the diagnostic threshold should be lower rather than higher. Even 2–3 strong bipolarity signs in an SUD patient warrant screening and mood stabilizer consideration. The best assessment window is during sustained abstinence (≥2 weeks; ideally 4+ weeks).

Screening Tools for Primary Care

Four well-validated screening tools can help primary care doctors identify possible bipolar spectrum disorder. Using two or more in combination improves diagnostic accuracy.

Tool	Items	Time	Sensitivity	Specificity	Best For
RMS	6	<2 min	88%	80%	Quick screen; best balance of sensitivity/specificity
MDQ	13+2	~5 min	71%	90%	High specificity; good for confirming bipolar I
BSDS	19+1	~5 min	70%	89%	Soft bipolar/spectrum; narrative format aids insight
HCL-32	32	~10 min	75–80%	51–63%	Detecting hypomania in depressed patients

Score Interpretation Thresholds

Tool	Positive Threshold	Interpretation
MDQ	≥7 symptoms + clustering + functional impact	Highly specific for BD-I; may miss BD-II and spectrum
MDQ (relaxed)	≥5 symptoms (without clustering)	Better sensitivity for bipolar spectrum (sens 0.91, spec 0.67)
BSDS	≥13 total score	Optimal balance; captures soft bipolar; narrative helps patients self-recognize
HCL-32	≥14 items endorsed	Good sensitivity but lower specificity; best for detecting hypomania
RMS	≥4 of 6 items	Quick, pragmatic; best for BD-I; preferred by 81% of providers over MDQ

Recommended Strategy

Start with the RMS (6 items, under 2 minutes) as a quick gate. If positive, follow up with the BSDS (better for BD-II/spectrum) or MDQ (better for BD-I). For a comprehensive evaluation, use the Bipolarity Index (clinician-rated, 5 domains). Use the navigation tabs above to access each interactive tool.

Rapid Mood Screener (RMS)

The RMS is a 6-item validated screening tool that takes under 2 minutes. It has the best balance of sensitivity (88%) and specificity (80%) of all bipolar screening instruments. Preferred by 81% of providers over the MDQ.

Positive threshold: ≥4 of 6 items endorsed

0 / 6

RMS Score

Negative screen — bipolar unlikely based on RMS alone

Digital Bipolarity Index

The Bipolarity Index was developed by Gary Sachs, MD at Harvard. It is the most clinically sophisticated bipolar assessment instrument, scoring across 5 domains with a continuous confidence metric. This is the first-ever interactive digital version.

Sensitivity 0.91, Specificity 0.90 at cutoff ≥50. Score range: 0–100.

0 / 100

Bipolarity Index Score

Low confidence for bipolar diagnosis

Score Range	Confidence Level	Clinical Action
0–24	Low confidence	Bipolar unlikely; treat as unipolar
25–49	Moderate confidence	Bipolar possible; further evaluation warranted
50–74	High confidence	Bipolar probable; initiate mood stabilizer
75–100	Very high confidence	Bipolar highly likely; treat as bipolar; refer to psychiatry

DIG FAST: Recognizing Hypomania

Many patients do not recognize hypomania because it can feel "normal" or even good. The DIG FAST mnemonic helps systematically check for hypomanic symptoms. For a hypomanic episode, 3+ symptoms must be present for at least 4 days (DSM-5).

0 / 7

DIG FAST Symptoms Present

Below threshold for hypomanic episode (<3 symptoms)

Key Distinction for Patients with SUD

When assessing hypomania in a patient who uses substances, ask specifically about times when they were NOT using. Substance-induced "highs" do not count for diagnosis. Also ask about periods immediately after stopping substances — withdrawal-related mood elevation can be a bipolar indicator.

Patient Self-Assessment: "Have I Ever Been Hypomanic?"

This can be given directly to the patient. It uses everyday language to help recognize whether they may have experienced periods of hypomania or mania in the past.

Instructions for the Patient: Think about times in your life when you were NOT using alcohol or drugs. Were there periods — lasting at least a couple of days — when you felt noticeably different from your usual self? Check each statement that applies to you.

0 / 16

Items Endorsed by Patient

Low likelihood of prior hypomania (0–3 items)

DSM-5 Mixed Features Screener

Mixed features are drastically under-detected in primary care. The DSM-5 "with mixed features" specifier applies when a patient in a depressive episode shows 3 or more of the following manic/hypomanic symptoms simultaneously. Mixed states carry the highest suicide risk of any mood state.

For the "with mixed features" specifier: patient must meet full criteria for a depressive episode AND have ≥3 of the following during most days of the episode.

0 / 7

Mixed Features Present

Does not meet threshold for mixed features specifier (<3)

Clinical Significance of Mixed Features

Mixed states carry the highest suicide risk of any mood state
Antidepressant monotherapy can worsen mixed features
Mixed features strongly suggest bipolar spectrum even without clear hypomanic episodes
Best treated with mood stabilizers (Depakote/valproate, atypical antipsychotics); avoid antidepressant monotherapy
Up to 40% of depressed bipolar patients have mixed features at any given time

Red Flag Pattern Engine: Treatment Response Analysis

A patient's history of antidepressant response provides critical diagnostic clues. Check each pattern that applies to your patient. The engine analyzes the combination and provides a bipolar probability assessment.

0

Red Flag Risk Points

No red flags identified — treatment history does not suggest bipolarity

Bipolar vs Unipolar Depression: Key Differences

Feature	Bipolar Depression	Unipolar Depression
Age of onset	Earlier (teens to mid-20s)	Later (late 20s–40s)
Family history	Bipolar disorder in relatives	Depression in relatives
Episode count	More numerous, shorter episodes	Fewer, longer episodes
Episode duration	Typically <3 months	Often 6–12 months
Sleep pattern	Hypersomnia (oversleeping)	Insomnia (more common)
Appetite	Hyperphagia (overeating)	Decreased appetite
Psychomotor	Retardation (slowed)	Agitation (more common)
Energy	Leaden paralysis	Fatigue, low energy
Mood quality	Mood lability, irritability, mixed features	Persistent low mood, guilt
Psychosis	More likely during depression	Less common
Suicidality	Higher rates of attempts	Present but lower rates
Diurnal variation	Worse in morning	Variable
Seasonality	More seasonal patterns	Less seasonal
Substance use	Very high comorbidity (40–70%)	Lower comorbidity
Antidepressant response	Poor/worsening; may trigger mania	Generally responsive
Anxiety comorbidity	High (with racing thoughts)	High (but less racing thoughts)
Post-episode	May feel "high" or energized	Gradual improvement

Sources: Cuellar et al., Clin Psychol Rev 2005; Leonpacher et al., Psychol Med 2015; Smith et al., Br J Psychiatry 2013

SUD + Bipolar: Interactive Decision Tree

Walk through this decision tree to determine if a substance-using patient has underlying bipolar disorder. Answer each question — the tree adapts based on your answers and provides specific guidance.

Is your patient currently using substances?

Yes — actively using

No — sober ≥2 weeks

Sober <2 weeks

Which substances?

Select the primary substance. Each affects bipolar assessment differently.

Alcohol

Cannabis

Stimulants (cocaine, meth, Adderall)

Opioids

Good — this is the best assessment window

With ≥2 weeks sobriety, screening tools are more reliable. Did mood episodes occur BEFORE substance use began?

Yes — mood problems came first

No — substances came first

Unclear / simultaneous

Early Sobriety: Diagnostic Caution Required

Wait if possible. Substance withdrawal can mimic both mania (stimulant withdrawal agitation, alcohol withdrawal hyperarousal) and depression (post-stimulant crash, opioid withdrawal dysphoria). Ideally reassess at 2–4 weeks sobriety.

If you can't wait (suicidality, severe symptoms): Use family history and collateral informants as your strongest diagnostic tools. Family members can often report mood episodes that predate substance use.

Key questions now:

"Before you started using, did you ever have periods of high energy, little sleep, or unusual confidence?"
"Has anyone in your family been diagnosed with bipolar disorder?"
"During your longest period of sobriety, did your moods still swing?"
"Do you tend to use MORE when you feel energized and 'up,' or only when you're down?"

Even in early sobriety, 2–3 strong bipolarity signs in an SUD patient warrant a mood stabilizer trial. The diagnostic threshold should be LOWER, not higher.

Reference: Diagnostic Challenges Table

+

Critical Interview Questions for Substance-Using Patients

"Before you started using alcohol/drugs regularly, did you ever have periods of high energy, little need for sleep, or unusual confidence?"

"During your longest period of sobriety, did your moods still go up and down?"

"Do you tend to use substances more when you feel 'up' and energized, or only when you feel down?"

"Has anyone ever told you that you were acting 'manic' or 'hyper' when you were sober?"

"When you feel depressed, do you also feel restless, irritable, or have racing thoughts at the same time?"

"How old were you when you first felt depressed? And when you first started using substances?"

"Has anyone in your family been diagnosed with bipolar disorder?"

"When you were on Prozac, did it make you feel agitated, wired, or worse in any way?"

Comprehensive Treatment Guide

12 modules covering everything you need to treat bipolar disorder in primary care

You Can Do This

If you're reading this, you've already done the hardest part — recognizing that your patient might have bipolar disorder. Most doctors miss this entirely. You didn't. That puts you ahead of the curve, and your patient is lucky to have you.

You may be thinking: "I'm not a psychiatrist. Should I really be treating this?" The answer is yes. Here's why:

50%+

of bipolar patients are managed entirely in primary care

77%

of bipolar patients see their PCP more often than any specialist

6 mo+

average wait for a new psychiatry appointment in most areas

69%

were misdiagnosed by other doctors before someone got it right

Why YOU Are Perfectly Positioned to Treat This

You know your patient. You've seen them over months or years. You know their baseline. A psychiatrist meeting them for the first time doesn't have that advantage.
You manage complex medications already. Diabetes, hypertension, thyroid disease — you titrate medications, monitor labs, and adjust doses all the time. Mood stabilizers are no more complicated than metformin or levothyroxine.
You catch the whole picture. Bipolar disorder affects sleep, weight, metabolic health, cardiovascular risk, and substance use. As a primary care doctor, you're already monitoring all of these.
Your patient trusts you. They may be reluctant to see a psychiatrist due to stigma. But they'll take a medication from you.
The medications are straightforward. You don't need to know 50 drugs. You need to know 3–4 really well, and we're going to teach you exactly those.

What You're Doing vs. What Most Doctors Do

What Most Doctors Do (Unintentionally Harmful)	What You're About to Do (Evidence-Based)
Prescribe an antidepressant alone for "treatment-resistant depression"	Recognize that treatment resistance may signal bipolarity and start a mood stabilizer
Increase the SSRI dose when the patient doesn't improve	Question why the SSRI isn't working and screen for bipolar
Miss hypomania because the patient never mentions "feeling good"	Actively screen with validated tools (RMS, MDQ, BSDS, DIG FAST)
Refer to psychiatry and wait 6+ months while the patient deteriorates	Start treatment now and refer for complex cases
Tell the patient "it's just depression" for years	Give them the correct diagnosis and change their life trajectory

You Are Literally Saving Your Patient

The average bipolar patient is misdiagnosed for 5–8 years and sees 3+ doctors before someone gets it right. During that time, they receive antidepressants that make them worse, they lose jobs, relationships fall apart, and their suicide risk climbs. By recognizing this and treating it correctly, you are changing that trajectory. That is not a small thing. That is extraordinary medicine.

What You Need to Know vs. What You Don't

You DO Need to Know	You DON'T Need to Know
3–4 first-line medications and how to start them	Every atypical antipsychotic and their receptor binding profiles
Basic lab monitoring for Lithium and mood stabilizers	Complex polypharmacy regimens for treatment-resistant cases
When a patient needs emergency intervention	How to manage acute psychotic mania (that's inpatient psychiatry)
How to talk to patients about their diagnosis	The neuroscience of bipolar pathophysiology
When to refer to psychiatry (and what to do while waiting)	How to manage electroconvulsive therapy or clozapine

Why am I telling you this?

Treatment Algorithm: The Master Decision Tree

This flowchart walks you through the entire treatment decision process. Start at the top and follow the arrows. Click any box to expand details.

STEP 1: What Are We Treating?

First, determine the bipolar subtype and current phase.

Bipolar I

Has had at least one manic episode (7+ days or hospitalization)

Bipolar II

Hypomania (less severe, 4+ days) with major depressive episodes

↓

STEP 2: What Phase Are We Treating?

Treatment varies dramatically depending on the current mood phase.

Acute Mania

Elevated mood, decreased sleep, impulsivity, possibly psychotic

Acute Depression

Low mood, anhedonia, fatigue, suicidal ideation — the most common presentation

Maintenance

Stable — goal is preventing relapse

Mixed Features

Depression + mania symptoms simultaneously — highest suicide risk

↓

STEP 3: First-Line Medication by Phase (CANMAT/ISBD 2018+2023)

Phase	First-Line (Start Here)	Second-Line (If #1 Fails)	Avoid
Acute Mania (BP I)	Lithium, Seroquel (quetiapine), Depakote (divalproex), Abilify (aripiprazole), Risperdal (risperidone), Saphris (asenapine), Vraylar (cariprazine) Combinations preferred: Li or DVP + atypical antipsychotic	Zyprexa (olanzapine), Tegretol (carbamazepine), Geodon (ziprasidone)	Antidepressants (can worsen mania)
Acute Depression (BP I)	Seroquel (quetiapine), Latuda (lurasidone), Vraylar (cariprazine), Caplyta (lumateperone), Lithium, Lamictal (lamotrigine) Latuda (lurasidone), Vraylar (cariprazine), & Caplyta (lumateperone) all FDA-approved for BP depression	Symbyax (olanzapine-fluoxetine), Lithium + Lamictal (lamotrigine)	Antidepressant monotherapy (destabilizes mood)
Acute Depression (BP II)	Seroquel (quetiapine), Latuda (lurasidone), Vraylar (cariprazine), Caplyta (lumateperone) Most evidence for BP II: Seroquel. Latuda, Vraylar, Caplyta also FDA-approved for BP depression	Lithium, Lamictal (lamotrigine)	Antidepressant monotherapy
Maintenance (BP I)	Lithium, Seroquel (quetiapine), Depakote (divalproex), Lamictal (lamotrigine), Abilify (aripiprazole), Saphris (asenapine)	Zyprexa (olanzapine), Risperdal (risperidone) LAI, Tegretol (carbamazepine)	Antidepressant monotherapy
Mixed Features	Depakote (divalproex), Saphris (asenapine), Abilify (aripiprazole), Vraylar (cariprazine) CANMAT/ISBD mixed states recs	Zyprexa (olanzapine), Geodon (ziprasidone), Seroquel (quetiapine)	Antidepressants (especially dangerous here)

↓

STEP 4: Start Treatment

Pick ONE medication

Start simple. Monotherapy first. For most primary care situations, start with Seroquel (quetiapine) (works across all phases), Lamictal (lamotrigine) (best for depression prevention), or Lithium (gold standard, anti-suicide).

Start at lowest effective dose

See the "Starting Your First Med" tab for exact doses and titration schedules for each medication.

Follow up in 1–2 weeks

Check tolerability, side effects, and early response. Most medications need 2–4 weeks for initial effect and 4–8 weeks for full response.

↓

STEP 5: Assess Response at 4–8 Weeks

Full Response

PHQ-9 < 5, stable mood, functioning well

Continue current regimen → Maintenance

Partial Response

Some improvement but residual symptoms

Optimize dose → If max dose, add augmentation

No Response

No meaningful improvement after adequate trial

Switch medication → If 2 failures, refer to psychiatry

↓

WHEN TO ESCALATE

Send to the ER if: active suicidal plan, psychosis, severe mania with dangerous behavior, or inability to care for self.

Refer to psychiatry (non-emergency) if: failed 2+ adequate medication trials, complex comorbidities, pregnancy, or rapid cycling.

See the "Emergency Recognition" and "When to Refer" tabs for detailed criteria.

Why am I telling you this?

Starting Your First Medication: A Baby Steps Guide

This is the step-by-step walkthrough. You're going to pick one medication, start it, and follow up. That's it. One medication. One patient. One step at a time.

You're going to do great.

STEP 1: Pick One Medication

For your first bipolar patient, pick the medication that best fits their situation:

If the patient is mostly...	Start with...	Why this one?
Depressed (most common presentation)	Seroquel (quetiapine) 50 mg at bedtime	Works for bipolar depression AND prevents mania. Helps sleep immediately. Broadest evidence base.
Depressed and worried about weight gain	Latuda (lurasidone) 20 mg with dinner	Effective for bipolar depression with minimal weight gain. Must take with 350+ calories.
Depressed and already on an antidepressant	Caplyta (lumateperone) 42 mg at bedtime	Recently FDA-approved as adjunct to antidepressants. If you suspect bipolar but aren't sure, adding Caplyta (lumateperone) can help whether it's truly bipolar or MDD.
Depressed and wants newest option	Vraylar (cariprazine) 1.5 mg at bedtime	FDA-approved for bipolar depression. Can increase to 3 mg after 1 month if needed. Watch for akathisia (~20%).
Depressed with recurrent episodes	Lamictal (lamotrigine) 25 mg daily	Best for preventing depressive relapse. Very well tolerated long-term. Slow titration required.
Manic or mixed	Lithium 300 mg at bedtime	Gold standard. Anti-suicide properties. Works for mania and maintenance. Requires lab monitoring.
Suicidal	Lithium 300 mg at bedtime	ONLY medication proven to reduce suicide risk in bipolar disorder. Start here if suicidality is present.

Not sure? Seroquel (quetiapine) is the safest first choice — it works across all phases of bipolar illness and doesn't require lab monitoring to start.

↓

STEP 2: Starting Dose (Exact mg)

Medication	Starting Dose	When to Take	Important Notes
Seroquel (quetiapine)	50 mg	At bedtime	Very sedating at first — that's actually helpful for sleep. Can increase by 50–100 mg every few days.
Latuda (lurasidone)	20 mg	With dinner (350+ calories)	MUST be taken with food or it doesn't absorb properly. This is the #1 reason it "doesn't work."
Caplyta (lumateperone)	42 mg	At bedtime	Only comes in one dose (42 mg). Recently approved as adjunct to antidepressants — great if you're unsure whether it's bipolar or MDD.
Vraylar (cariprazine)	1.5 mg	At bedtime	Start at 1.5 mg. Can increase to 3 mg after 1 month if needed. Watch for akathisia (~20% of patients).
Lamictal (lamotrigine)	25 mg	Morning or bedtime	MUST titrate slowly: 25mg x 2 wks → 50mg x 2 wks → 100mg x 1 wk → 200mg. Prevents deadly rash (SJS).
Lithium	300 mg	At bedtime	Get baseline labs FIRST: BMP (creatinine), TSH, CBC, pregnancy test. Level in 5 days at trough (12 hrs post-dose).

↓

STEP 3: What to Tell the Patient (Exact Words)

"Based on everything we've discussed, I believe your depression may be part of a condition called bipolar spectrum disorder. This is very common — it affects about 4% of people — and the good news is that it responds well to the right medication. The reason your antidepressant hasn't been working may be because this type of depression needs a different kind of medication called a mood stabilizer. I'm going to start you on [medication name] at a low dose. Most people tolerate it well. I want to see you back in [1–2 weeks] to see how you're doing. Do you have any questions?"

↓

STEP 4: When to See Them Back

Visit	Timing	What to Check
Visit 1	1–2 weeks	Tolerability, side effects, medication adherence, any worsening
Visit 2	4 weeks	Early response (PHQ-9), dose adjustment needed?, labs for Lithium
Visit 3	8 weeks	Full response assessment — is it working? Continue, adjust, or switch?
Maintenance	Every 3 months	Mood stability, side effects, labs (Lithium/Depakote (valproate)), adherence

↓

STEP 5: What to Check at Follow-Up

PHQ-9 score — Is the depression improving? (Target: 50%+ reduction by week 4)
Sleep — Better or worse? Too sedated?
Side effects — Weight gain? Sedation? Tremor? GI issues? Rash (Lamictal/lamotrigine)?
Suicidality — Has it decreased? Increased? New suicidal thoughts?
Mania/hypomania check — Any new elevated mood, decreased sleep need, impulsivity?
Medication adherence — "Are you taking it every day? Any doses missed?"
Labs (if on Lithium) — Lithium level at trough, BMP, TSH

↓

STEP 6: When and How to Increase the Dose

Medication	When to Increase	How Much	Target Dose Range
Seroquel (quetiapine)	Every 2–3 days if tolerated	50–100 mg increments	200–300 mg/day for depression; up to 800 mg for mania
Latuda (lurasidone)	After 1–2 weeks if tolerated	20 mg increments	40–120 mg/day (most respond at 40–80 mg)
Caplyta (lumateperone)	N/A — single dose	None (42 mg only)	42 mg/day (only available dose)
Vraylar (cariprazine)	After 1 month if needed	1.5 mg increments	1.5–3 mg/day for depression
Lamictal (lamotrigine)	Every 2 weeks (NEVER faster)	See fixed titration schedule	200 mg/day (some patients need 300–400 mg)
Lithium	Based on serum levels	300 mg increments	Level 0.6–0.8 mEq/L (typical dose 900–1200 mg/day)

↓

STEP 7: How Long to Wait Before Deciding

Medication	Earliest Improvement	Full Trial Duration	Don't Give Up Before...
Seroquel (quetiapine)	1–2 weeks	4–6 weeks at therapeutic dose	6 weeks at 300 mg
Latuda (lurasidone)	1–2 weeks	4–6 weeks at therapeutic dose	6 weeks at 60–80 mg
Caplyta (lumateperone)	1–3 weeks	4–6 weeks at 42 mg	6 weeks
Vraylar (cariprazine)	1–3 weeks	4–8 weeks (very long half-life)	8 weeks at 1.5–3 mg
Lamictal (lamotrigine)	4–6 weeks (slow titration)	8–12 weeks at 200 mg	12 weeks (it takes longer because of slow titration)
Lithium	1–2 weeks for mania; 4–6 for depression	6–8 weeks at therapeutic level	8 weeks at 0.6+ mEq/L

↓

STEP 8: What to Do If It's Not Working

Scenario	Action
Partial response (some improvement)	Optimize dose — make sure you're at the target dose range before switching. Many "failures" are actually underdosing.
No response after adequate trial	Switch to another first-line medication. Example: Seroquel (quetiapine) didn't work → try Lamictal (lamotrigine) or lithium.
Partial response at max dose	Augment — add a second medication. Example: Lamictal (lamotrigine) for depression prevention + Lithium for mood stability.
Failed 2+ adequate trials	Refer to psychiatry. This is now treatment-resistant and may need specialist combinations. Keep the patient on current meds while waiting for the appointment.

↓

STEP 9: Managing Side Effects (Quick Guide)

Side Effect	Which Meds?	Dangerous?	What to Do
Sedation	Seroquel/quetiapine (very common)	No	Give at bedtime. Often improves in 1–2 weeks. Reduce dose if severe.
Weight gain	Seroquel (quetiapine), Zyprexa (olanzapine), Lithium	Long-term metabolic risk	Monitor weight monthly. Consider switching to Latuda (lurasidone) or Lamictal (lamotrigine) if significant.
Tremor	Lithium	May indicate toxicity	Check Lithium level. If level OK: reduce dose or add propranolol 10–20 mg BID.
Rash	Lamictal (lamotrigine)	POTENTIALLY FATAL	STOP Lamictal (lamotrigine) immediately. Any rash in first 8 weeks = stop. Evaluate for Stevens-Johnson syndrome.
Nausea/GI	Lithium, Depakote (valproate)	No	Take with food. Use extended-release formulation. Usually improves over time.
Akathisia (restlessness)	Vraylar (~20%), Abilify (aripiprazole), Latuda (lurasidone)	Distressing; suicide risk	Reduce dose. Add propranolol. Switch medication if severe. Vraylar (cariprazine) has the highest akathisia risk among bipolar depression meds.
Thyroid changes	Lithium	Treatable	Monitor TSH every 6 months. If hypothyroid: add levothyroxine (don't stop Lithium).

See the "Side Effect Management" tab for the complete troubleshooting guide.

That's it. Nine steps. You just learned how to start treating bipolar disorder.

Your patient's life just changed for the better. Most doctors never get this far.

Why am I telling you this?

Medication Guide: Detailed Drug Cards

Click any medication card to expand full prescribing details, side effects, monitoring, and patient communication scripts.

Based on CANMAT/ISBD 2018+2023, APA, NICE, and Maudsley Prescribing Guidelines

Mood Stabilizers

Lithium (Lithobid, Eskalith)

The gold standard mood stabilizer — the only medication proven to reduce suicide risk in bipolar disorder

+

Category	Details
How it works	Natural salt that stabilizes mood by modulating neurotransmitter signaling and protecting brain cells. Exact mechanism still being studied after 70+ years of use.
FDA-approved for	Bipolar I (acute mania and maintenance). Used off-label for bipolar depression and bipolar II.
Starting dose	300 mg at bedtime (or 300 mg BID)
Titration	Increase by 300 mg every 3–5 days. Check level after each increase (5 days to steady state). Typical dose: 900–1200 mg/day.
Target level	0.6–0.8 mEq/L for maintenance. 0.8–1.0 mEq/L for acute mania. Draw level at trough (12 hours post-dose).
Time to effect	Mania: 1–2 weeks. Depression: 4–6 weeks. Full maintenance benefit: 6+ months.
Common side effects	Tremor (27%), GI upset/nausea (20%), increased thirst/urination (30%), weight gain (10–25%), cognitive dulling, acne
Dangerous side effects	Lithium toxicity (level >1.5): vomiting, coarse tremor, confusion, seizures. Call 911 if suspected. Also: renal impairment (long-term), hypothyroidism (20–30%), cardiac conduction changes.
Baseline labs	BMP (creatinine, eGFR), TSH, CBC, calcium, urinalysis, pregnancy test, ECG if >50 years old
Monitoring schedule	Lithium level: q3–5 days during titration, then q3 months x 1 year, then q6 months. TSH + creatinine: every 6 months. eGFR annually.
Drug interactions	NSAIDs (ibuprofen, naproxen) — increase Lithium level. ACE inhibitors, ARBs, thiazide diuretics — increase level. Dehydration, low-salt diet, vomiting/diarrhea — increase level and toxicity risk.
Special populations	Elderly: Lower doses, target 0.4–0.6 mEq/L. Pregnancy: Risk of Ebstein's anomaly (0.1–0.2%); discuss risks/benefits. Renal impairment: Reduce dose; may be contraindicated if eGFR <30.
What to tell patient	"This is a natural mineral salt that has been used for over 70 years and is the most proven treatment for bipolar disorder. It's the only medication that reduces suicide risk. You'll need regular blood tests to make sure the level is right — not too low (won't work) and not too high (side effects). Stay well hydrated, avoid ibuprofen, and don't change your salt intake suddenly."
Cost	Generic: $4–15/month (very affordable). On most $4 generic lists.

Depakote (valproate/divalproex)

Broad-spectrum mood stabilizer — particularly effective for mania, mixed states, and rapid cycling

+

Category	Details
How it works	Anticonvulsant that increases GABA (a calming brain chemical) and stabilizes electrical activity in the brain.
FDA-approved for	Bipolar I acute mania. Used off-label for mixed states, rapid cycling, and maintenance.
Starting dose	250 mg BID or 500 mg ER at bedtime
Titration	Increase by 250–500 mg every 3–5 days. Target level: 50–100 mcg/mL. For acute mania, can load at 20–30 mg/kg/day.
Target level	50–100 mcg/mL (some use 80–120 for acute mania). Typical dose: 1000–2000 mg/day.
Time to effect	Mania: 3–5 days (faster than Lithium). Less evidence for depression.
Common side effects	GI upset (25%), sedation, tremor, weight gain (significant), hair thinning/loss, elevated liver enzymes
Dangerous side effects	Hepatotoxicity (rare but potentially fatal, especially in children). Pancreatitis. Thrombocytopenia. PCOS-like syndrome in women (weight gain, menstrual irregularity).
Baseline labs	CBC with platelets, LFTs (hepatic panel), lipid panel, pregnancy test
Monitoring	Depakote (valproate) level + CBC + LFTs: monthly x 3, then every 6 months. Monitor weight and menstrual changes in women.
Drug interactions	DOUBLES Lamictal (lamotrigine) levels (halve the Lamictal dose if combining). Decreases oral contraceptive efficacy. Interacts with many anticonvulsants.
Special populations	PREGNANCY: CONTRAINDICATED. Category X. 7–10% risk of neural tube defects. Must use reliable contraception. Women of childbearing age: Use only if no alternatives and with contraception. Elderly: Lower doses due to decreased clearance.
What to tell patient	"This medication calms overactive electrical signals in the brain that cause mood swings. It works faster than Lithium for treating mania. You'll need blood tests to check the level and make sure your liver is handling it well. The most common side effect is some stomach upset and possibly weight gain."
Cost	Generic: $10–25/month. Depakote ER brand: much more expensive.

Lamictal (lamotrigine)

Best for preventing bipolar depression relapse — well tolerated, minimal weight gain, no lab monitoring needed

+

Category	Details
How it works	Stabilizes electrical activity by blocking sodium channels. Uniquely effective at preventing depressive episodes rather than manic episodes.
FDA-approved for	Bipolar I maintenance (preventing both mania and depression). Best evidence is for depression prevention.
Starting dose	25 mg once daily
CRITICAL: Titration schedule	MUST titrate slowly to prevent Stevens-Johnson Syndrome (SJS): Weeks 1–2: 25 mg/day Weeks 3–4: 50 mg/day Week 5: 100 mg/day Week 6+: 200 mg/day (target) If on Depakote (valproate): Halve ALL doses (12.5 mg start, target 100 mg) If stopped for 5+ days: RESTART from 25 mg (full re-titration required)
Target dose	200 mg/day (range 100–400 mg/day)
Time to effect	6–12 weeks (because of slow titration). Not a fast-acting medication. Best for long-term prevention.
Common side effects	Headache (25%), dizziness (14%), nausea, insomnia, benign rash (10% — not all rashes are SJS)
Dangerous: Rash / SJS	Stevens-Johnson Syndrome: Risk 0.08% with proper titration (1 in 1,250). Risk jumps to ~1% with fast titration. If ANY rash appears in first 8 weeks — STOP Lamictal (lamotrigine) immediately, even if rash looks benign. Refer to dermatology/ER if blistering, mucosal involvement, or fever.
Labs needed	None required for routine monitoring (major advantage over Lithium and Depakote (valproate))
Drug interactions	Depakote (valproate) DOUBLES Lamictal levels (halve dose). Tegretol (carbamazepine) HALVES Lamictal levels (double dose). Oral contraceptives decrease Lamictal levels (may need dose adjustment).
Special populations	Pregnancy: Relatively safer than Depakote (valproate)/lithium. Registry data shows ~2% malformation rate (near background). May need dose increase during pregnancy. Elderly: No specific dose adjustment. Renal/hepatic impairment: Reduce dose.
What to tell patient	"This medication is one of the best at preventing the depressive episodes that are the biggest part of bipolar disorder. The downside is that we have to start very slowly and increase gradually over about 6 weeks. This is because of a rare but serious rash that can happen if we go too fast. If you develop any rash at all in the first two months, stop the medication and call me immediately. Most rashes are harmless, but we have to check every one."
Cost	Generic: $4–15/month (very affordable).

Tegretol (carbamazepine)

Second-line mood stabilizer — effective but complex drug interactions limit its use

+

Atypical Antipsychotics

Seroquel (quetiapine)

The Swiss Army knife of bipolar treatment — works for mania, depression, mixed states, and maintenance

+

Category	Details
How it works	Blocks dopamine and serotonin receptors, with antihistamine properties that promote sleep. Works differently at different doses.
FDA-approved for	Bipolar I and II depression, bipolar I acute mania, bipolar I maintenance. One of the few medications with FDA approval for bipolar depression.
Starting dose	50 mg at bedtime (for depression). 100 mg/day for mania.
Titration	Depression: Increase to 100 mg day 2, 200 mg day 3, 300 mg day 4. Mania: Increase by 100 mg/day to 400–800 mg.
Target dose	Depression: 300 mg/day. Mania: 400–800 mg/day.
Time to effect	Sleep improvement: night 1. Depression: 1–2 weeks. Full response: 4–6 weeks.
Common side effects	Sedation (very common, 30%+), weight gain (15–25%), dry mouth, dizziness, orthostatic hypotension, constipation
Dangerous side effects	Metabolic syndrome (monitor glucose, lipids, weight), tardive dyskinesia (rare), QTc prolongation (rare). Diabetes risk: monitor fasting glucose at baseline, 12 weeks, then annually.
Labs needed	Baseline: fasting glucose, lipid panel, weight, waist circumference. Monitor: weight monthly x 3, then quarterly. Glucose and lipids at 12 weeks, then annually.
Drug interactions	CYP3A4 substrate — levels increased by ketoconazole, erythromycin. Levels decreased by Tegretol (carbamazepine), phenytoin. Additive sedation with alcohol, benzodiazepines.
Special populations	Elderly: Start lower (25 mg), titrate slower. Fall risk due to sedation. Pregnancy: Limited data; weigh risks/benefits. Diabetes: Use with caution; monitor closely.
What to tell patient	"This is a medication that works on several brain chemicals involved in mood regulation. It's one of the best-studied medications for bipolar depression. It will definitely make you sleepy at first, which is why we take it at bedtime — this can actually help if you've been having trouble sleeping. The sleepiness usually gets better over the first week or two. I'll be monitoring your weight and blood sugar because this medication can affect metabolism."
Cost	Generic: $10–30/month. Brand (Seroquel XR): much more expensive.

Latuda (lurasidone)

Excellent for bipolar depression with minimal weight gain — updated to first-line in 2023 CANMAT update

+

Caplyta (lumateperone)

Newest FDA-approved option for bipolar depression — also approved as adjunct to antidepressants

+

Category	Details
How it works	Modulates serotonin, dopamine, and glutamate simultaneously. Blocks 5-HT2A, partial agonist at D2 (presynaptic), and inhibits serotonin reuptake at low doses.
FDA-approved for	Bipolar I and II depression (monotherapy or adjunctive with Lithium or Depakote (valproate)). Also recently approved as adjunct to antidepressants for bipolar depression.
Why this matters for PCPs	If your patient is on an antidepressant and you suspect bipolar but aren't sure, you can add Caplyta (lumateperone). It will help whether the diagnosis turns out to be truly bipolar or even major depressive disorder. This makes it uniquely useful in the diagnostic gray zone.
Dose	42 mg once daily at bedtime. Only comes in one dose — no titration needed. Simple.
Time to effect	Depression improvement: 1–3 weeks. Full response: 4–6 weeks.
Common side effects	Somnolence/sedation (10%), dizziness (5%), nausea (3%), dry mouth (2%). Generally well tolerated.
Key advantages	Minimal weight gain. Low metabolic impact. Low EPS/akathisia risk compared to other atypicals. Simple one-dose regimen. Works as adjunct to antidepressants (unique advantage).
Labs needed	Baseline metabolic panel (standard for antipsychotics). Less likely to cause metabolic abnormalities than most competitors.
Drug interactions	CYP3A4 substrate. Avoid strong CYP3A4 inhibitors (ketoconazole) and inducers (rifampin, Tegretol (carbamazepine)).
What to tell patient	"This is one of the newest medications for bipolar depression. You take just one capsule at bedtime. It tends to be well tolerated — minimal weight gain and generally doesn't cause the restlessness that some other medications in this class can cause. It can also work alongside your current antidepressant if you're on one."
Cost	Brand only (Caplyta): approximately $1200–1500/month. No generic yet. Manufacturer savings card available for eligible patients.

Abilify (aripiprazole)

First-line for acute mania and maintenance — activating (not sedating), weight-neutral relative to others

+

Zyprexa (olanzapine) & Symbyax (olanzapine-fluoxetine)

Very effective but significant metabolic side effects limit long-term use

+

Vraylar (cariprazine)

FDA-approved for bipolar depression, mania, and mixed episodes — watch for akathisia (~20%)

+

Risperdal (risperidone) & Geodon (ziprasidone)

Second-line options for acute mania — less commonly used in primary care for bipolar

+

What About Antidepressants?

This is one of the most important sections in this entire guide. Antidepressant use in bipolar disorder is the single most common treatment error in primary care.

Rule	Explanation
NEVER give an antidepressant ALONE	Antidepressant monotherapy in bipolar disorder can trigger mania, increase cycling, worsen mixed states, and increase suicidality. This is true for ALL antidepressants.
WITH a mood stabilizer: Sometimes OK	An antidepressant can be cautiously added to a mood stabilizer for persistent depression, but should be the LAST step, not the first.
Safest antidepressant: Bupropion	Lowest mania switch rate (~10% vs 25% for SSRIs). No sexual side effects. No weight gain. First choice if an antidepressant is needed.
Second safest: SSRIs	Sertraline and citalopram have reasonable data. Moderate mania switch risk (~15–25%). Always pair with mood stabilizer.
AVOID: SNRIs (venlafaxine, duloxetine)	Highest mania switch rate among antidepressants (~30%). Norepinephrine component is activating.
AVOID: TCAs (amitriptyline, nortriptyline)	High mania switch rate. Multiple dangerous side effects. No role in bipolar treatment.

Key message: If your patient is already on an antidepressant alone and you now suspect bipolar disorder — START a mood stabilizer FIRST, then gradually taper the antidepressant over 4–8 weeks. Do NOT abruptly stop the antidepressant.

Why am I telling you this?

Phase-Specific Treatment Guides

Bipolar treatment changes dramatically depending on which phase your patient is in right now. Click each phase below.

Acute Mania / Hypomania: What to Do Right Now

Your patient is presenting with elevated mood, decreased need for sleep, increased energy, pressured speech, grandiosity, and/or impulsive behavior. Here's what to do.

First: Is This an Emergency?

Send to ER NOW if:	Can Manage Outpatient if:
Psychosis (hallucinations, delusions, paranoia) Not sleeping at all for 2+ days Dangerous behavior (spending life savings, physical aggression) Cannot care for self (not eating, wandering) Suicidal or homicidal ideation Family fears for safety	Hypomania (mild elevation, still functioning) Sleeping at least some (3–4 hours) No psychosis Can attend appointments Supportive family at home Willing to take medication

Outpatient Mania Treatment: Step by Step

1. Start medication immediately

First choice for primary care: Seroquel (quetiapine) 100 mg at bedtime, increase to 200–400 mg over 3–5 days. Sedation is actually helpful here — the patient needs to sleep. Alternative: Lithium 300 mg BID, titrate to 0.8–1.0 mEq/L. If already on Lithium: Check level and optimize to 0.8–1.0.

2. Address sleep urgently

Sleep deprivation fuels mania. If Seroquel (quetiapine) isn't sedating enough, short-term benzodiazepine (lorazepam 0.5–1 mg at bedtime x 1–2 weeks) can bridge until the mood stabilizer kicks in. Strict sleep hygiene instructions.

3. If patient is on an antidepressant — STOP IT

Antidepressants can trigger and maintain mania. Taper over 1–2 weeks (faster taper than for depression — mania takes priority). For fluoxetine (long half-life), can usually just stop.

4. See them back in 3–5 days

Mania can escalate quickly. Short follow-up interval is essential. Phone check at 48 hours. Have family call immediately if behavior worsens.

How Do I Know the Mania Is Getting Better?

Sleep returns — this is the first and most important sign. When they start sleeping 5–6+ hours, mania is resolving.
Speech slows — less pressured, more organized
Insight returns — "I think I was really out of it last week"
Energy normalizes — no longer cleaning the house at 3 AM
Family reports improvement — collateral from family is often more reliable than the patient's self-report

Timeline: Most outpatient hypomania resolves within 1–2 weeks with proper medication. Full mania may take 3–6 weeks.

Acute Bipolar Depression: The Most Common Presentation

This is the phase you'll see most often. Patients with bipolar disorder spend 3x more time depressed than manic. The key difference from unipolar depression: the treatment is fundamentally different.

The #1 Rule: Do NOT treat bipolar depression with an antidepressant alone. This is the most common mistake in all of psychiatry. Antidepressants alone can trigger mania, increase cycling, worsen mixed states, and raise suicide risk.

First-Line Treatment for Bipolar Depression (CANMAT/ISBD)

Medication	Starting Dose	Target	Onset	Best For
Seroquel (quetiapine)	50 mg HS	300 mg	1–2 wk	Bipolar I or II depression + insomnia. Broadest evidence.
Latuda (lurasidone)	20 mg w/ food	40–80 mg	1–2 wk	Bipolar I depression. Best if weight gain is a concern.
Caplyta (lumateperone)	42 mg HS	42 mg (one dose)	1–3 wk	BP I/II depression. Also adjunct to antidepressants — great if unsure if bipolar or MDD.
Vraylar (cariprazine)	1.5 mg HS	1.5–3 mg	1–3 wk	BP I depression/mania/mixed. Can increase to 3 mg after 1 month. Watch akathisia (~20%).
Lamictal (lamotrigine)	25 mg	200 mg	6–12 wk	Long-term depression prevention. Best for recurrent depressive episodes.
Lithium	300 mg HS	0.6–0.8 mEq/L	4–6 wk	Suicidal patients. Anti-suicide evidence is unique to lithium.

Practical recommendation: Start with quetiapine (fast onset, helps sleep, broadest evidence), lurasidone (if weight is a concern), or Caplyta (if patient is already on an antidepressant and you're unsure whether it's bipolar or MDD). Vraylar (cariprazine) is another strong option but watch for akathisia (~20%). Add Lamictal (lamotrigine) for long-term depression prevention.

My Patient Is Suicidal — What Do I Do?

Assess severity: Passive ideation ("I wish I weren't alive") vs. active plan ("I've been thinking about taking all my pills"). Use the Columbia Suicide Severity Rating Scale (C-SSRS) or simply ask directly.
If active plan or intent: Do NOT let the patient leave. Call 911 or have them escorted to the ER. This is a psychiatric emergency.
If passive ideation without plan: Start Lithium (strongest anti-suicide evidence). Create a safety plan. Restrict access to means (firearms, stockpiled medications). Increase visit frequency to weekly.
Involve family: With patient's permission, inform a trusted family member. Give them crisis numbers: 988 Suicide & Crisis Lifeline, Crisis Text Line (text HOME to 741741).
Document thoroughly: Note the assessment, interventions, safety plan, and follow-up plan.
Consider urgent psychiatry referral: If available within 1–2 weeks, refer. If wait is longer, begin treatment yourself — do NOT just refer and wait.

Expected Timeline for Improvement

Week	What to Expect	Action
1–2	Sleep may improve first. Energy may start to return. Mood often lags behind.	Check tolerability. Watch for emergence of mania/hypomania.
3–4	PHQ-9 should show some improvement (3+ point drop). Patient reports "better days."	If no improvement: optimize dose. If side effects: address or switch.
6–8	Full response expected for Seroquel (quetiapine), Latuda (lurasidone), Caplyta, and Vraylar (cariprazine). Lamictal (lamotrigine) still titrating.	Assess: Full response? Partial? None? Decide next step.
10–12	Lamictal (lamotrigine) reaches full therapeutic dose and effect.	Full assessment. If no response after 2 adequate trials → refer to psychiatry.

Maintenance: Preventing Relapse

Your patient is stable. Now the goal shifts to keeping them stable. This is where the real work of bipolar treatment happens — and where the real life-changing benefits accumulate.

Why Maintenance Is Critical

90%

Relapse rate within 5 years WITHOUT maintenance medication

40–60%

Relapse rate WITH maintenance medication

50%

of patients stop medication within 1 year

6 mo

Average time to relapse after stopping medication

Best Medications for Long-Term Maintenance

Medication	Prevents Mania?	Prevents Depression?	Anti-Suicide?	Overall Rank
Lithium	Strong	Moderate	YES (unique)	#1 overall
Seroquel (quetiapine)	Strong	Strong	No data	#2 overall
Lamictal (lamotrigine)	Weak	Strong	No data	Best for depression-predominant
Depakote (valproate)	Strong	Weak	No data	Best for mania-predominant
Abilify (aripiprazole)	Strong	Weak	No data	Good adjunct for mania prevention

How Long to Continue Treatment

The honest answer: usually lifelong. Bipolar disorder is a chronic, relapsing illness like diabetes or hypertension. Here's how to explain that to patients:

"Think of this medication like blood pressure medicine. High blood pressure doesn't go away when you feel better — it comes back when you stop the medication. Bipolar disorder works the same way. The medication is working precisely because it's keeping your mood stable. If we stop it, the episodes come back, usually within a few months. This isn't a failure — it's the nature of the condition. And the good news is that with consistent treatment, most people do very well long-term."

Monitoring Schedule for Stable Patients

What	How Often	Why
Office visit	Every 3 months	Mood check, medication adherence, side effects, life stressors
PHQ-9 / mood rating	Every visit	Objective tracking; catches early relapse
Lithium level	Every 6 months (after 1st year)	Ensure therapeutic range; catch toxicity
Creatinine / eGFR	Every 6–12 months	Monitor for Lithium nephrotoxicity
TSH	Every 6–12 months	Lithium-induced hypothyroidism (20–30%)
Fasting glucose + lipids	Annually	Metabolic monitoring (especially Seroquel (quetiapine), Zyprexa (olanzapine))
Weight / BMI	Every visit	Catch early weight gain; consider switching if significant

"My Patient Wants to Stop Their Medication"

This is one of the most common conversations you'll have. Don't panic. Don't lecture. Here's what works:

Validate their feelings: "I understand. Taking medication every day is a commitment, and it's natural to wonder if you still need it."
Share the data honestly: "Here's what the research shows: about 90% of people who stop their mood stabilizer have another episode within a few years. Most relapse within 6 months."
Identify their specific concern: Side effects? Cost? Stigma? Feeling "not themselves"? Pregnancy planning? Each concern has a specific solution.
Offer alternatives to stopping completely: "What if we try a lower dose?" or "What if we switch to something with fewer side effects?"
Never use threats or guilt. That destroys the therapeutic relationship.
If they insist on stopping: Taper slowly (over 2–4 weeks minimum). Increase visit frequency. Create a relapse prevention plan. Make sure they know they can restart anytime without judgment.

Mixed Features: The Most Dangerous Mood State

Mixed features = depression + manic symptoms at the same time. The patient feels miserable, hopeless, and suicidal — but with the energy, agitation, and impulsivity of mania. This combination creates the highest risk for suicide of any mood state.

What Mixed Features Look Like in Your Office

Depressed mood + racing thoughts ("I feel terrible but my mind won't stop")
Low mood + irritability/agitation (pacing, can't sit still, snapping at family)
Hopelessness + increased energy (they have the energy to act on suicidal thoughts)
Crying + pressured speech
Fatigue + insomnia (exhausted but can't sleep)

Treatment of Mixed Features

Preferred Medications	AVOID
Depakote (divalproex) — best evidence for mixed states Saphris (asenapine) — FDA-approved for mixed episodes Abilify (aripiprazole) — FDA-approved for mixed episodes Vraylar (cariprazine) — FDA-approved for mixed episodes Seroquel (quetiapine) — reasonable option with broad efficacy	All antidepressants — can worsen agitation and suicidality Lamictal (lamotrigine) alone — insufficient anti-manic effect

Monitoring for Rapid Cycling

Mixed states often signal or evolve into rapid cycling (4+ episodes per year). Monitor closely for:

Mood shifts every few days or weeks
Antidepressant use (common trigger for rapid cycling)
Thyroid dysfunction (check TSH — subclinical hypothyroidism can drive cycling)
Substance use (alcohol and stimulants destabilize mood cycling)

Rapid cycling that doesn't respond to first-line treatment should be referred to psychiatry.

Why am I telling you this?

Side Effect Management: "What Do I Do When..."

Click any scenario below for specific guidance on what to do, what to switch to, and how to counsel the patient.

"My patient gained 20 pounds"

+

"My patient is too sedated"

+

"My patient has hand tremor"

+

"My patient's labs are abnormal"

+

"My patient got a rash on Lamictal"

+

"My patient is pregnant or wants to become pregnant"

+

"My patient is elderly"

+

Why am I telling you this?

Emergency Recognition: When to Send to the ER

These are clear, unambiguous criteria. When in doubt, it is ALWAYS better to send them. You will never be faulted for erring on the side of caution with a psychiatric emergency.

SEND TO ER IMMEDIATELY IF:

Active Suicidal Ideation with Plan

"I've been thinking about how I would do it" / has a specific method / access to means / has set a timeline. Do NOT let them leave the office. Call 911 or have them transported.

Psychotic Symptoms

Hallucinations (hearing voices, seeing things), delusions (believing they are God, FBI is following them), paranoia, disorganized thinking. Psychosis requires inpatient evaluation.

Severe Mania with Dangerous Behavior

Not sleeping at all, spending life savings, hypersexual encounters, physical aggression, driving recklessly, making catastrophic decisions. Cannot be managed outpatient.

Inability to Care for Self

Not eating, not drinking water, not sleeping for 3+ days, wandering, unable to maintain hygiene, unable to stay safe at home.

Lithium Toxicity

Severe symptoms: coarse tremor (not fine), vomiting, confusion, slurred speech, unsteady gait, seizures. Hold Lithium, check level, send to ER for monitoring and possible dialysis.

Catatonia

Not moving, not speaking, rigid posture, waxy flexibility, staring. Medical emergency — can be fatal. Requires inpatient treatment (often lorazepam IV).

How to Communicate with the ER

When you send a patient to the ER, call ahead. This makes a dramatic difference in how quickly and seriously your patient is evaluated.

What to tell the ER:
"I'm sending you [patient name], a [age]-year-old with known/suspected bipolar disorder. They are presenting with [specific symptoms]. Their current medications are [list]. Their last Lithium level was [X] on [date]. I am concerned about [specific emergency: suicidality with plan / psychotic mania / Lithium toxicity]. They [have/do not have] a support person with them. Please evaluate for [inpatient admission / toxicity management / safety assessment]."

What to Send with the Patient

Current medication list with doses
Most recent labs (Lithium level, metabolic panel)
Brief clinical summary (diagnosis, how long treated, current concern)
Your contact information so the ER can call you
Any advance directives or psychiatric advance directives on file

How to Follow Up After an ER Visit or Hospitalization

Timing	Action
Within 48 hours	Call the patient or family to check status. Were they admitted? Discharged? What were the ER recommendations?
Within 1 week	See the patient in your office. Review any medication changes made in the ER/hospital. Ensure continuity.
Ongoing	Increase visit frequency to weekly x 4 after a crisis. Safety plan in place. Consider adding psychiatry if not already involved.

The period immediately after an ER visit or hospitalization is the HIGHEST risk time for suicide in bipolar disorder. Close follow-up is critical.

Remember: If you're not sure whether it's an emergency, it's ALWAYS better to send them.

988 Suicide & Crisis Lifeline (call or text 988) | Crisis Text Line (text HOME to 741741)

Patient Communication Scripts

Word-for-word scripts you can use or adapt. These were crafted to destigmatize, build trust, and improve medication adherence. Click each scenario to expand.

"How to tell a patient they have bipolar disorder"

+

"Why you need a mood stabilizer instead of an antidepressant"

+

"Why this is a lifelong condition"

+

"How to explain side effects without scaring them"

+

"My patient says: I don't want to take medication"

+

"How to involve family members"

+

"How to discuss the genetic component"

+

"My patient stopped their medication cold turkey"

+

"My patient is pregnant and on valproate"

+

"The family is calling because they think the patient is manic"

+

"My patient wants to try CBD instead of medication"

+

Why am I telling you this?

Treatment Response Tracker

Enter your patient's current treatment details, and this tool will provide a recommendation based on published treatment algorithms (CANMAT/ISBD, APA, Texas Algorithm).

Current Treatment Information

Current Medication

Current Dose

Weeks on Current Regimen

Response Level

Side Effects Experienced (check all that apply)

Number of Prior Adequate Medication Trials That Failed

Recommendation

Fill in the treatment information above to receive a recommendation.

Why am I telling you this?

Side-by-Side Medication Comparison

Select two medications to compare them head-to-head across efficacy, side effects, monitoring, and practical considerations.

Medication A

VS

Medication B

Longitudinal Treatment Tracker

Track your patient's progress across multiple visits. Add each visit's data to see mood, weight, and medication response trends over time.

Add Visit Data

Visit Date

PHQ-9

Mood (1-10)

Sleep (hrs)

Weight (lbs)

Medication

Response

Side Effects

Treatment Timeline

No visits recorded yet. Add visit data above to see your patient's treatment trajectory.

Should I Order Genetic Testing?

Pharmacogenomic testing (like GeneSight) analyzes how a patient's genes affect medication metabolism. Here's when it helps, when it doesn't, and how to use the results.

Decision: Should I Order It?

YES — Consider Testing When:

Failed 2+ adequate medication trials
Severe or unexpected side effects at normal doses
Patient is a poor metabolizer (suspect: needs tiny doses OR huge doses for effect)
Multiple psychiatric medications being tried
Patient/family requests it
Planning to start a medication with narrow therapeutic index (Lithium, valproate)

NO — Not Needed When:

First medication trial (try standard approach first)
Patient responded well to current medication
Nonadherence is the reason for treatment failure (not pharmacogenetics)
Active substance use confounding assessment

How GeneSight Works

Step	Details
1. Order	Simple cheek swab in your office. Takes 30 seconds. You order it — no specialist needed.
2. Processing	Results in 2–3 business days. Analyzes 12 genes affecting 57+ psychiatric medications.
3. Results	Color-coded report: GREEN = use as directed. YELLOW = use with caution (may need dose adjustment). RED = significant gene-drug interaction (consider alternative).
4. Cost	Maximum $330 out-of-pocket (income-based sliding scale). $0 for Medicare Part B and Medicaid. Most commercial insurance covers it after 1 failed trial.

How to Interpret Results

What it DOES tell you:

How fast or slow your patient metabolizes specific medications (CYP2D6, CYP2C19, CYP3A4)
Whether a medication is likely to cause more side effects than expected
Whether standard dosing is likely to produce therapeutic or subtherapeutic levels

What it does NOT tell you:

Which medication will definitely work (it's about metabolism, not efficacy prediction)
Anything about Lithium (Lithium is renally excreted, not hepatically metabolized)
Whether the patient has bipolar disorder (it's not a diagnostic test)

Key Genes for Bipolar Medications

Gene	Medications Affected	Clinical Impact
CYP2D6	Aripiprazole, risperidone, some antidepressants	Poor metabolizers: higher blood levels, more side effects at standard doses. Ultra-rapid metabolizers: may need higher doses.
CYP2C19	Citalopram, escitalopram, some benzodiazepines	Poor metabolizers: slower clearance, higher risk of QTc prolongation with citalopram.
CYP3A4	Quetiapine, lurasidone, lumateperone, cariprazine	Affects metabolism of most atypical antipsychotics used in bipolar depression.
CYP1A2	Olanzapine, clozapine	Smoking induces CYP1A2 — smokers may need higher olanzapine doses. Stopping smoking = sudden increase in drug levels.
UGT1A4	Lamotrigine	Affects lamotrigine metabolism. Valproate inhibits this enzyme (why you halve lamotrigine dose with valproate).

Bottom Line: Order pharmacogenomic testing after 2+ medication failures. It saves an average of $1,000/year in medication costs and reduces trial-and-error.

Sources: GeneSight GUIDED trial (Am J Psychiatry 2019), Hall-Flavin et al. (Pharmacogenomics 2013)

When to Refer to Psychiatry (Non-Emergency)

Not every bipolar patient needs a psychiatrist. But some do. Here's exactly when to refer and how to do it well.

Clear Indications for Psychiatry Referral

Indication	Why	Urgency
Failed 2+ adequate medication trials	This is now treatment-resistant bipolar — specialist combinations (clozapine, ECT, complex polypharmacy) may be needed	Weeks
Complex comorbidities	Active substance use disorder + bipolar, personality disorder + bipolar, PTSD + bipolar — complex interactions require specialist management	Weeks
Pregnancy (current or planned)	Medication risk/benefit decisions require specialist knowledge. Ideally preconception planning.	Weeks
Rapid cycling not responding	4+ episodes/year despite first-line treatment — may need thyroid optimization, complex combinations	Weeks
Psychotic features (current or history)	Bipolar with psychosis is a more severe variant requiring specific medication strategies	Days to weeks
Persistent suicidality despite treatment	Suicide risk management benefits from specialist input and potentially ECT or clozapine consideration	Days
Diagnostic uncertainty	You're not sure if it's bipolar, schizoaffective, BPD, or complex PTSD — specialist diagnostic assessment	Weeks to months
Patient requests specialist care	Patient preference is always valid	Weeks

How to Write a Good Referral Letter

A good referral letter gets your patient seen faster and ensures better care. Include:

Re: [Patient Name], DOB [date]

Dear Colleague,

I am referring this [age]-year-old [gender] for psychiatric evaluation and medication management for suspected/confirmed bipolar [I/II/spectrum] disorder.

Clinical History: [Brief summary — when depression started, any manic/hypomanic episodes, family history, substance use]

Screening Results: [RMS score, MDQ result, Bipolarity Index score, PHQ-9 score]

Current Medications: [List with doses and duration]

Treatment Trials: [What has been tried and the response to each]

Reason for Referral: [Specific question — e.g., "Failed two adequate trials of mood stabilizer. Requesting evaluation for treatment-resistant bipolar depression and medication optimization."]

Current Concerns: [Suicidality level, specific symptoms, functional impairment]

Please contact me at [phone/fax] with your recommendations. I will continue managing this patient's primary care needs and am happy to co-manage psychiatric medications with your guidance.

Sincerely, [Your name]

What to Do While Waiting for the Psychiatry Appointment

DO NOT just refer and stop treatment. The wait can be months.

Continue current medications. Even if they're not working perfectly, stopping creates risk of destabilization.
Continue monitoring. Schedule regular follow-ups (monthly minimum) while waiting.
Optimize what you can. If the current medication is partially working, consider dose optimization or adding a complementary agent.
Manage the crisis if one occurs. You are still this patient's doctor. If they become suicidal or manic, manage per the Emergency Recognition guidelines.
Keep detailed records. The psychiatrist will need a comprehensive history. Track PHQ-9 scores, medication trials, side effects, and clinical observations.
Consider telepsychiatry. Wait times are often shorter for telepsychiatry. Many platforms offer consultations within 1–2 weeks.

When You Do NOT Need to Refer

Mild-to-moderate bipolar II responding to first-line medication — you can manage this
Stable patient on maintenance medication — routine monitoring is primary care
New diagnosis with straightforward presentation — start treatment, refer only if first trial fails
Patient with good support system and mild symptoms — you've got this

Most mild-to-moderate bipolar patients can be effectively managed in primary care with the tools in this guide. You are doing this.

Why am I telling you this?

Quick Reference Cards

Printable one-page references you can keep in your pocket, tape to your office wall, or hand to patients. Click "Print" to print any card.

Medication Quick Reference Card

Medication	Starting Dose	Target	Key Monitoring	Top Side Effect	Best For
Lithium	300 mg HS	0.6–0.8 mEq/L	Level, Cr, TSH q6mo	Tremor, thirst	Suicidality, mania, maintenance
Seroquel (quetiapine)	50 mg HS	300 mg (dep) / 400–800 (mania)	Glucose, lipids, weight	Sedation, weight gain	All phases; sleep
Lamictal (lamotrigine)	25 mg (slow titrate!)	200 mg (6+ weeks)	Rash watch x 8 wks	Rash (SJS risk)	Depression prevention
Latuda (lurasidone)	20 mg w/ food	40–80 mg	Metabolic (minimal)	Akathisia, nausea	BP I depression; weight-neutral
Caplyta (lumateperone)	42 mg HS	42 mg (one dose)	Metabolic (minimal)	Sedation, dizziness	BP depression; adjunct to ADs; low akathisia
Vraylar (cariprazine)	1.5 mg HS	1.5–3 mg	Metabolic	Akathisia (~20%)	BP depression, mania, mixed
Depakote (valproate)	250 mg BID	50–100 mcg/mL	Level, LFTs, CBC, plt	Weight, GI, hair loss	Mania, mixed, rapid cycling
Abilify (aripiprazole)	10–15 mg	15–30 mg	Metabolic	Akathisia	Mania prevention
Zyprexa (olanzapine)	5–10 mg HS	15–20 mg	Glucose, lipids, weight!	Major weight gain	Acute mania (last resort)

Created by Dr. Arnold Shapiro, MD | CANMAT/ISBD 2018+2023 | For clinical decision support only

Lamictal (lamotrigine) Titration Schedule (Prevent SJS)

Week	Standard Dose	If on Valproate (Halve All Doses)	If on Carbamazepine (Double All Doses)
Weeks 1–2	25 mg once daily	12.5 mg once daily (or 25 mg every other day)	50 mg once daily
Weeks 3–4	50 mg once daily	25 mg once daily	100 mg/day (divided BID)
Week 5	100 mg once daily	50 mg once daily	200 mg/day (divided BID)
Week 6+	200 mg once daily (TARGET)	100 mg once daily	300–400 mg/day (divided BID)

CRITICAL SAFETY RULES:

NEVER increase faster than this schedule
If ANY rash appears in the first 8 weeks: STOP Lamictal (lamotrigine) immediately
If patient misses 5+ days: RESTART from 25 mg (full re-titration required)
SJS risk: 0.08% with slow titration; up to 1% with fast titration

Follow-Up Visit Quick Checklist

☐ PHQ-9 score: _____ (previous: _____)

☐ Mood self-rating (1–10): _____

☐ Suicidality screen: None / Passive / Active

☐ Medication adherence: Taking as prescribed? Y / N

☐ Side effects: _______________

☐ Weight: _____ lbs (change: _____ lbs)

☐ Sleep: _____ hrs/night (quality: good / fair / poor)

☐ Hypomania/mania screen: Negative / Positive

☐ Substance use screen: None / Active / In recovery

☐ Labs due? Li level / TSH / Cr / VPA level / Metabolic / None

☐ Dose change: Continue / Increase / Decrease / Switch / Add

☐ Next visit in: _____ weeks

Emergency Criteria: When to Send to the ER

URGENT (same-day phone/visit): New onset mania/hypomania | Suicidal ideation (passive) | Medication side effect concern | Family reporting significant behavioral change

ROUTINE (next scheduled visit): Stable patient with mild symptom fluctuation | Dose adjustment discussion | Lab results review | Medication refill

When in doubt, it is ALWAYS better to send them. | 988 Suicide & Crisis Lifeline | Crisis Text Line: text HOME to 741741

Patient Education Handout: "Understanding Your Bipolar Diagnosis"

What Is Bipolar Disorder?

Bipolar disorder is a condition where your brain's mood regulation system doesn't work as well as it should. This causes your mood to swing between low periods (depression) and high periods (mania or hypomania). About 1 in 25 people have some form of it. It is NOT a character flaw — it is a medical condition, like diabetes or high blood pressure.

Why Mood Stabilizers Instead of Antidepressants?

Regular antidepressants treat one direction (pushing mood up). But in bipolar disorder, your mood already goes up and down. A mood stabilizer works like cruise control — it keeps your mood in a steady range, preventing both the lows and the highs.

What to Expect from Treatment

Most medications take 2–6 weeks to reach full effect
Side effects are usually worst in the first 1–2 weeks and then improve
Do NOT stop your medication without talking to your doctor first
If you have any side effects that concern you, call your doctor — don't just stop the medication

Things You Can Do to Help

Sleep: Keep a regular sleep schedule. Go to bed and wake up at the same time every day. Sleep disruption is the #1 trigger for mood episodes.
Exercise: 30 minutes of moderate exercise most days helps stabilize mood
Avoid alcohol and drugs: They destabilize mood and interfere with medication
Keep appointments: Regular follow-up catches problems early
Track your mood: Notice patterns. Tell your doctor about changes.

When to Call Your Doctor Immediately

Thoughts of suicide or self-harm
Not sleeping at all for 2+ days
Feeling "out of control" or making decisions you normally wouldn't
Any rash (if you're taking Lamictal (lamotrigine))
Confusion, severe tremor, or vomiting (if you're taking Lithium)

Crisis Resources

988 Suicide & Crisis Lifeline: Call or text 988 (24/7)
Crisis Text Line: Text HOME to 741741
Emergency: Call 911 or go to your nearest emergency room

Created by Dr. Arnold Shapiro, MD — Board-Certified Psychiatrist, 35+ Years Clinical Experience

Why am I telling you this?

Diagnostic Decision Flowchart

Use this flowchart for any depressed patient with possible bipolar features. Adapted from ISBD and CANMAT guidelines.

STEP 1: Initial Presentation

Patient presents with depression + any of: SUD comorbidity, suicidal ideation, antidepressant nonresponse, early onset (<20), family history of bipolar, mood lability

↓

STEP 2: Screen for Bipolarity

Administer RMS (quick gate) → MDQ + BSDS if positive. Ask DIG FAST questions. Obtain collateral history from family/friends. Review full medication history.

↓

STEP 3: Evaluate Results

Count bipolarity signs (checklist): 0–1 = Likely unipolar → standard treatment. 2–3 = Possible bipolar spectrum → mood stabilizer + monitoring. 4+ = Probable bipolar → treat as bipolar; refer to psychiatry.

↓

STEP 4: Treatment Decision

If bipolar spectrum suspected: Taper antidepressant (if on one). Start mood stabilizer (quetiapine, Lamictal (lamotrigine), or Lithium). Address SUD concurrently. Safety plan for suicidality.

↓

STEP 5: Monitor and Adjust

Reassess every 1–2 weeks initially. PHQ-9 for depression. Watch for emergent hypomania. If unclear after 3 months: psychiatric referral for definitive diagnosis.

Interactive Life Chart

Based on the NIMH Life Chart Methodology. Plot your patient's mood history during the clinical interview. Click on each time period to set the mood state, then add medications and life events. This creates a visual picture of the illness course.

Patient Mood History

Click on cells in each row to mark the mood state for that time period. The chart builds as you click.

Severe Mania
Hypomania
Euthymia
Mild Depression
Severe Depression

Time Scale

Add Events & Medications

Mark medication changes and life events on the timeline.

Time Period

Event / Med Change

How to Use This Chart

During the interview: Ask "Looking back over the past year, can you tell me about your mood month by month?" Click the corresponding mood level for each period.
Look for patterns: Rapid cycling (4+ episodes/year), seasonal patterns, or medication response correlations
Add context: Mark when medications were started/changed and major life events. These often correlate with mood shifts.
Collateral information: Have a family member review the chart — they often remember mood episodes the patient has forgotten

Visual Risk Dashboard

One-glance summary of all completed assessment scores. Complete any of the screening tools, then return here to see your patient's risk profile at a glance. Scores update automatically.

0

Signs Checklist

LOW

0/6

RMS Screen

NEG

0

Bipolarity Index

LOW

0/7

DIG FAST

LOW

0/16

Patient Self

LOW

0/7

Mixed Features

LOW

0

Red Flags

LOW

Overall Assessment: Complete Screening Tools First

Complete any of the assessment tools above, then click "Refresh Dashboard" to see the integrated risk profile.

Personalized Patient Handout Generator

Generate a customized take-home handout for your patient based on their specific diagnosis and treatment plan. Fill in the details below and click "Generate Handout."

Patient Information

Patient First Name

Diagnosis

Prescribed Medication

Dose

Key warning signs to watch for (personalized)

Key Statistics and Comorbidity Rates

Lifetime Comorbidity Rates in Bipolar Disorder

Any substance use disorder56%

Anxiety disorders51%

Alcohol use disorder42%

Personality disorders36%

Suicide attempts33%

ADHD31%

PTSD24%

The Misdiagnosis Problem

69%

Initially misdiagnosed

5–8 yr

Average years to correct diagnosis

48%

Seen by 3+ doctors before diagnosis

~60%

Treated with antidepressants first

Bipolar Prevalence in Substance Use Populations

Diagnostic Criteria Used	Prevalence in SUD Patients
DSM-IV criteria	24%
Mood Disorder Questionnaire (MDQ)	29.9%
Ghaemi & Goodwin criteria	29.9%
Akiskal classification (broadest bipolar spectrum)	48.2%
General population rate (for comparison)	1–3%

Auto-Generated Clinical Summary

This summary compiles results from all completed assessments in this session. Complete any of the interactive tools above, then return here to generate a comprehensive clinical note suitable for the medical record.

Key Takeaways for the Clinical Scenario Patient

Bipolar spectrum disorder should be the working diagnosis given: high-dose SSRI nonresponse, heavy substance use, suicidal ideation, and presentation with refractory depression.
Antidepressant monotherapy should be discontinued — fluoxetine 80 mg should be tapered gradually while a mood stabilizer is started.
Even without a confirmed manic episode, 2–3 strong bipolarity signs in a substance-using patient are sufficient to warrant treatment as bipolar spectrum.
First-line treatment: Seroquel (quetiapine), Lamictal (lamotrigine), or lithium. Lithium has the strongest anti-suicide evidence.
Substance use treatment must be concurrent, not sequential.
Psychiatric referral is strongly recommended for this complexity level.
Collateral history from family/friends is essential.

Key Academic References

Ghaemi SN et al. Diagnostic guidelines for bipolar disorder: a summary of the ISBD Diagnostic Guidelines Task Force Report. Bipolar Disord. 2008.

Ghaemi SN et al. Clinical research diagnostic criteria for bipolar illness (CRDC-BP). Int J Bipolar Disord. 2022;10:23.

Huang H et al. Treating Bipolar Disorder in Primary Care. Int J Gen Med. 2022;15:8557-8572.

Smith DJ et al. Bipolar spectrum disorders in primary care. Br J Gen Pract. 2010;60(574):e209-e216.

Born C et al. Comorbid Bipolar and Alcohol Use Disorder. Front Psychiatry. 2021;12:660432.

Leonpacher D et al. Distinguishing bipolar from unipolar depression. Psychol Med. 2015;45(11):2437-2446.

Dines M et al. Critical Overview of Screening Tools for Detecting Bipolar Disorders. Actas Esp Psiquiatr. 2025;53(5).

Sachs GS. The Bipolarity Index: a clinician-rated measure of diagnostic confidence. J Clin Psychiatry. 2015.

Thase ME et al. Rapid Mood Screener (RMS) validation. Prim Care Companion CNS Disord. 2023.

Biggan J et al. Diagnostic Disagreements in Bipolar Disorder: Role of SUD. Depression Res Treat. 2012.

Gonda X, Rihmer Z. Antidepressant-Resistant Depression and Bipolarity. Depression Res Treat. 2011.

Patel R et al. Do antidepressants increase mania risk? BMJ Open. 2015;5(12):e008341.

Gitlin MJ. Antidepressants in bipolar depression. Int J Bipolar Disord. 2018;6:25.

Samimi Ardestani SM et al. Dual Diagnosis of Bipolar and Substance Abuse. J Dual Diagn. 2024.

Sayyah M et al. Screening instruments for bipolar disorder: meta-analysis. Rev Bras Psiquiatr. 2022;44(3):349-358.

Cuellar AK et al. Distinctions between bipolar and unipolar depression. Clin Psychol Rev. 2005;25(3):307-339.

All content created by Dr. Arnold Shapiro, MD. For clinical decision support only — does not replace professional medical judgment. All treatment decisions should be made in consultation with a qualified healthcare provider.

Challenge	How Substances Interfere	Solution
Symptom Mimicry	Stimulants mimic mania. Alcohol withdrawal causes agitation, insomnia, grandiosity.	Assess only during periods of sobriety (≥2 weeks). Ask family about sober behavior.
Symptom Masking	Alcohol/sedatives can dampen manic symptoms, making hypomania invisible.	Ask: "Do you drink MORE when you feel energized/restless?" Self-medication patterns are diagnostic clues.
Mood Destabilization	Chronic substance use disrupts mood regulation, increasing cycling and mixed states.	Look for mood episodes that precede substance use onset. Family history is more reliable.
Memory Impairment	Chronic use impairs recall of past mood episodes.	Collateral history from family is essential.
Diagnostic Disagreement	Clinicians disagree more on bipolar dx when SUD is present.	Use multiple screening tools. Longitudinal observation over 3–6 months.

Category	Details
FDA-approved for	Bipolar I acute mania, maintenance. Symbyax (olanzapine-fluoxetine) combination for bipolar I depression.
Starting dose	Zyprexa (olanzapine): 5–10 mg at bedtime. Symbyax: 6/25 mg (olanzapine/fluoxetine).
Target dose	Mania: 15–20 mg. Maintenance: 5–15 mg. Symbyax: 6–12/25–50 mg.
Major concern: Weight gain	Average weight gain: 5–10 kg in first year. Highest weight gain of any atypical antipsychotic. Also: dyslipidemia, insulin resistance, diabetes risk.
Common side effects	Sedation (very common), weight gain (very common), increased appetite, dry mouth, dizziness, constipation
Bottom line for PCP	Very effective but metabolic side effects are serious. Best reserved for acute mania when rapid control is needed, or bipolar depression when other options have failed. Monitor metabolic parameters closely. Not ideal for long-term use as first choice.
Cost	Generic Zyprexa (olanzapine): $10–20/month. Symbyax: $200–500/month (expensive, no generic).

Category	Details
How it works	Partial agonist at dopamine D2 and D3 receptors (D3-preferring). Similar mechanism to Abilify (aripiprazole) but with D3 preference.
FDA-approved for	Bipolar I depression, acute mania, and mixed episodes. One of few agents approved for bipolar depression.
Starting dose	1.5 mg once daily at bedtime.
Titration	Can increase to 3 mg after 1 month if needed. For depression, 1.5–3 mg/day is the therapeutic range. For mania: 3–6 mg/day.
Key feature	Very long half-life (2–4 weeks for active metabolites). Effects persist weeks after stopping. Steady state takes 1–2 weeks. This means dose changes take a long time to show effect.
WARNING: Akathisia (~20%)	Approximately 20% of patients will experience akathisia (inner restlessness, inability to sit still). This is the most common reason patients stop this medication. Warn patients proactively. Manage with dose reduction or propranolol 10–20 mg BID. If severe, switch to a different medication.
Common side effects	Akathisia (~20%), EPS (15%), nausea, insomnia, weight gain (modest)
What to tell patient	"This is an effective newer medication for bipolar depression. We start with a very low dose at bedtime. Some people — about 1 in 5 — feel restless or like they can't sit still. If that happens, let me know right away and we can adjust. Don't just suffer through it."
Cost	Brand only (Vraylar): $1000–1500/month. No generic yet. Insurance coverage varies. Manufacturer savings card available.

Medication	Best For	Starting Dose	Key Issue	Cost
Risperdal (risperidone)	Acute mania (first-line per CANMAT)	1–2 mg/day, target 2–6 mg	High EPS risk, prolactin elevation (gynecomastia, menstrual irregularity)	Generic: $5–15/mo
Geodon (ziprasidone)	Acute mania, mixed episodes	40 mg BID with food	QTc prolongation (get baseline ECG). Must take with food. Weight-neutral.	Generic: $15–30/mo

Which meds cause this?	Zyprexa/olanzapine (worst, avg 5–10 kg/yr), Seroquel/quetiapine (moderate, avg 2–4 kg), Lithium (moderate, avg 2–5 kg), Depakote/valproate (moderate). Latuda (lurasidone), Caplyta (lumateperone), and Lamictal (lamotrigine) are weight-neutral.
What to try first	Lifestyle intervention: 150 min/week exercise, dietary counseling. If on Seroquel (quetiapine) at high dose, try reducing. If on Lithium, check TSH (hypothyroidism causes weight gain).
What to switch to	Latuda (lurasidone) (minimal weight gain), Caplyta (lumateperone) (weight-neutral), Lamictal (lamotrigine) (weight-neutral), or Abilify (aripiprazole) (relatively weight-neutral). Switch gradually — never abruptly stop the current medication.
Adjunctive options	Metformin 500–1000 mg BID (evidence for antipsychotic-induced weight gain, off-label). Topiramate (off-label, also helps mood but can cause cognitive dulling).
What to tell patient	"Weight gain is a real and frustrating side effect. It doesn't mean we have to accept it. We have several strategies: adjusting your dose, switching to a medication less likely to cause weight gain, or adding a medication to help. Let's find the right balance between mood stability and side effects you can live with."

Category	Details
How it works	Anticonvulsant that blocks sodium channels and reduces nerve firing in the brain.
FDA-approved for	Bipolar I acute mania and mixed episodes.
Starting dose	200 mg BID
Titration	Increase by 200 mg/day every 3–7 days. Target level: 4–12 mcg/mL. Typical dose: 600–1600 mg/day.
Common side effects	Dizziness, sedation, diplopia (double vision), ataxia, nausea, hyponatremia
Dangerous side effects	Aplastic anemia, agranulocytosis (rare). SJS/TEN (HLA-B*1502 testing recommended in Asian populations). Hepatotoxicity. SIADH/hyponatremia.
Drug interactions	Potent CYP3A4 inducer — speeds up metabolism of many drugs including oral contraceptives, Lamictal (lamotrigine), Seroquel (quetiapine), and many others. Auto-induces its own metabolism. Very complex interactions — check ALL other medications.
Bottom line for PCP	Generally NOT recommended as a first choice in primary care due to complex drug interactions and monitoring requirements. Best reserved for psychiatrist management or when other options have failed.
Cost	Generic: $10–30/month.

Category	Details
How it works	Blocks dopamine D2 and serotonin 5-HT2A receptors. Unique partial agonist activity at 5-HT1A (antidepressant-like effect).
FDA-approved for	Bipolar I depression (monotherapy and adjunctive with Lithium or Depakote (valproate)).
Starting dose	20 mg with dinner
Titration	Can increase to 40 mg after 1 week, then 60–80 mg based on response. Max: 120 mg/day.
CRITICAL: Must take with food	MUST be taken with at least 350 calories. Without food, absorption is reduced by 50%. This is the #1 reason for apparent treatment failure. Take with dinner.
Time to effect	Depression: 1–2 weeks. Full response: 4–6 weeks.
Common side effects	Nausea (10%), akathisia/restlessness (9%), sedation (7%), EPS/stiffness (5%)
Key advantage	Minimal weight gain (average 0.3 kg in trials). Minimal metabolic effects. Among the best-tolerated atypical antipsychotics.
Labs needed	Baseline metabolic monitoring (same as other antipsychotics). Less likely to cause metabolic abnormalities.
Drug interactions	CYP3A4 substrate. Contraindicated with strong CYP3A4 inhibitors (ketoconazole) and inducers (rifampin, Tegretol (carbamazepine)). Max 40 mg with moderate inhibitors (diltiazem).
Special populations	Elderly: No dose adjustment needed. Renal impairment: Max 80 mg if CrCl <50. Hepatic impairment: Max 40 mg (moderate), 20 mg (severe).
What to tell patient	"This medication is very effective for bipolar depression and has the big advantage of not causing much weight gain. The most important thing to know is that you MUST take it with dinner — at least a normal-sized meal. Without food, your body can't absorb it properly. Some people feel a little restless at first; let me know if that happens and we can adjust."
Cost	Generic available since 2023: $15–50/month. Brand (Latuda): very expensive ($1500+/month).

Category	Details
How it works	Partial dopamine agonist ("dopamine stabilizer") — turns dopamine up when it's too low, down when it's too high.
FDA-approved for	Bipolar I acute mania/mixed, maintenance. Adjunct to Lithium or Depakote (valproate) for mania.
Starting dose	10–15 mg once daily
Target dose	15–30 mg/day for mania. 15 mg/day for maintenance.
Common side effects	Akathisia/restlessness (23% — most common reason for discontinuation), insomnia, nausea, headache
Key concern	Akathisia (inner restlessness, can't sit still) is very common and very distressing. Can be mistaken for anxiety. Warn patients and manage with dose reduction or propranolol.
Special note	NOT effective for acute bipolar depression (limited evidence). Best for mania prevention and acute mania treatment.
Cost	Generic: $10–25/month.

Which meds cause this?	Seroquel/quetiapine (most common), Zyprexa (olanzapine), Depakote (valproate), Lithium at higher levels. Latuda (lurasidone), Caplyta (lumateperone), and Lamictal (lamotrigine) rarely cause significant sedation.
Dose timing strategy	Move the entire dose to bedtime (if not already). This turns the side effect into a sleep benefit. Seroquel (quetiapine) at bedtime is actually better for sleep architecture.
Dose reduction	For Seroquel (quetiapine) depression: therapeutic dose is 300 mg, but some respond at 150–200 mg. Try reducing. For Depakote (valproate): check level — may be supratherapeutic.
What to switch to	Latuda (lurasidone) (less sedating), Caplyta (lumateperone) (minimal sedation), Lamictal (lamotrigine) (non-sedating), or Abilify (aripiprazole) (activating rather than sedating).
Timeline	Seroquel (quetiapine) sedation often improves after 1–2 weeks as tolerance develops. Encourage the patient to give it 2 weeks before deciding it's intolerable.

First step	Check Lithium level immediately. Tremor can be the first sign of Lithium toxicity. If level >1.2: reduce dose. If >1.5: hold medication, recheck in 24 hrs.
If level is therapeutic	Fine postural tremor is common at therapeutic levels (27% of patients). Usually mild and tolerable. Worsened by caffeine and anxiety.
Management	Propranolol 10–20 mg BID or TID (very effective for Lithium tremor). Reduce caffeine. Consider switching to Lithium ER (smoother levels). If severe despite these measures, consider switching to an alternative mood stabilizer.
Red flags	Coarse tremor, ataxia (unsteady gait), confusion, slurred speech, vomiting = Lithium toxicity. Hold Lithium, check level, go to ER if severe.

Lab Finding	Most Likely Cause	Action
Elevated TSH	Lithium (20–30% develop hypothyroidism)	Add levothyroxine. Do NOT stop Lithium — hypothyroidism is easily treated. Target TSH 1–3.
Elevated creatinine	Lithium (long-term nephrotoxicity)	If mild rise: reduce dose, monitor q3 months. If eGFR <45: consider switching off lithium. Nephrology referral if eGFR <30.
Elevated liver enzymes	Depakote (valproate)	Mild elevation (<3x ULN): monitor q2 weeks. If >3x ULN or symptoms (jaundice, fatigue): stop Depakote (valproate). Hepatology referral.
Low platelets	Depakote (valproate)	If >100K: monitor. If <100K: reduce dose. If <50K or bleeding: stop Depakote (valproate).
Elevated fasting glucose	Seroquel (quetiapine), Zyprexa (olanzapine)	If prediabetic (100–125): lifestyle intervention + monitor q3 months. If diabetic (≥126): consider switching medication. Start diabetes management per guidelines.
Elevated lipids	Seroquel (quetiapine), Zyprexa (olanzapine)	Statin if indicated per cardiovascular risk. Consider switching to metabolically neutral agent (lurasidone, Caplyta, or Lamictal (lamotrigine)).
Low sodium	Carbamazepine (SIADH)	If Na >130: monitor. If Na <130: reduce dose or switch. If Na <125: urgent — hold Tegretol (carbamazepine).

Immediate action	STOP Lamictal (lamotrigine) immediately. Any rash in the first 8 weeks of treatment requires stopping.
Benign rash (most common)	Simple maculopapular rash without systemic symptoms. About 10% of patients get a benign rash. It resolves after stopping.
Stevens-Johnson Syndrome (SJS)	Blistering, mucosal involvement (mouth, eyes, genitals), fever, flu-like symptoms, skin pain. THIS IS A MEDICAL EMERGENCY. Send to ER immediately. Risk: 0.08% with proper titration, up to 1% with fast titration.
Can you restart?	If the rash was clearly benign and mild: some clinicians re-challenge with an even slower titration after full resolution. However, this should generally be done by a specialist. If any suspicion of SJS: NEVER rechallenge.
Prevention	Follow the slow titration schedule exactly (25 mg x 2 wk, 50 mg x 2 wk, 100 mg x 1 wk, 200 mg). If patient missed doses for 5+ days: restart from 25 mg. If on Depakote (valproate): halve all doses.

Medication	Pregnancy Risk	Recommendation
Depakote (valproate)	CONTRAINDICATED. 7–10% neural tube defect risk. Cognitive effects on child.	MUST switch before conception. Do not use in women of childbearing age without reliable contraception.
Lithium	Risk of Ebstein's anomaly (0.1–0.2%, lower than previously thought). Floppy infant syndrome in 3rd trimester.	Discuss risk/benefit. If bipolar is severe, continuing Lithium may be safer than stopping. Fetal echocardiogram at 16–20 weeks. Monitor levels closely (dose changes needed).
Lamictal (lamotrigine)	Relatively safe. ~2% malformation rate (near background rate). Best-studied mood stabilizer in pregnancy.	First choice if mood stabilizer needed in pregnancy. Levels drop during pregnancy — monitor and increase dose as needed.
Seroquel (quetiapine)	Limited data. Some gestational diabetes risk.	Can be continued if needed. Monitor glucose closely. Lowest effective dose.
Latuda (lurasidone)	Very limited data.	Generally switch to a better-studied option if possible.
Caplyta (lumateperone)	Very limited data (new drug).	Switch to a better-studied option if possible.
Vraylar (cariprazine)	Very limited data.	Switch to a better-studied option if possible.

General principle	"Start low, go slow." All doses should be 25–50% lower than adult doses. Titrate more slowly. Monitor more frequently.
Lithium	Target lower levels: 0.4–0.6 mEq/L (vs. 0.6–0.8 in younger adults). Higher renal sensitivity. Monitor renal function more frequently. Drug interactions with common medications (NSAIDs, ACE inhibitors, diuretics).
Seroquel (quetiapine)	Start at 25 mg (not 50 mg). Fall risk from sedation and orthostatic hypotension. FDA black box: increased mortality risk in elderly with dementia-related psychosis (NOT bipolar — but be aware).
Lamictal (lamotrigine)	Good choice for elderly — generally well tolerated, no metabolic effects, no sedation. Standard titration schedule applies.
Depakote (valproate)	Increased sedation, tremor, and thrombocytopenia risk. Lower doses needed. Monitor LFTs and platelets more frequently.
Key concerns	Polypharmacy (check all interactions), fall risk, cognitive effects, dehydration risk (increases Lithium toxicity), renal function decline.